Participated · Series B · Jun 2025

Commons Clinic operates a vertically integrated, physician-led specialty care platform that unites advanced diagnostics, personalized care pathways, and interventional procedures into a single accountable system. It launched Wholebody by Commons Clinic, a multi-specialty suite that provides comprehensive diagnostics and direct specialist treatments across musculoskeletal, cardiovascular, women’s health, metabolic, orthopedic, gastrointestinal, chronic pain, and preventive oncology care. Each Wholebody patient program includes up to three specialty consults via Commons Clinic’s national expert network and priority placement into a vetted FastPass network of primary care partners for accelerated, contiguous care. The organization emphasizes early detection, tailored prevention, and rapid intervention using technologies such as genetic testing (BRCA), coronary plaque assessment, and multi-cancer screening (Galeri) to create immediate, actionable pathways to treatment. Commons highlights its history of musculoskeletal innovation and plans to extend that playbook across cardiac, metabolic, cancer, and women’s health service lines under physician leadership. The company is based in Los Angeles and uses its vertically integrated model to reduce costs while improving specialty access and outcomes. Commons Clinic operates an integrated health system focused on spine, orthopedics, and pain management, combining physicians, branded care centers, surgical facilities and a native virtual clinic to deliver end-to-end care. Its platform converges value-based care, clinicians, ambulatory facilities and surgical centers to improve the patient experience. The company offers all-inclusive care programs for procedures including total joint replacements and spinal fusions. Founded in 2021 and based in Los Angeles, Commons Clinic raised a $19.5M Series A that brought its total funding to $33.5M. The company intends to use the proceeds to expand operations and broaden its business reach. Leadership includes co-founders Nick Aubin (CEO) and Paulo da Costa (COO); the company also added new board members following the round.

Participated · Series A · Feb 2025

Posterity Health delivers comprehensive male reproductive and hormonal healthcare via telehealth, at-home diagnostics, and in-person services, covering fertility optimization, hormone management, vasectomies, and related procedures. Its platform uses technology-driven triage and decision-support tools to match patients with reproductive urologists and guide appropriate testosterone therapy. The company emphasizes early male evaluation to reduce unnecessary female treatments and to detect underlying health risks linked to male infertility. Posterity cites an actuarial analysis showing employers save $2.30 for every $1 spent on male fertility care and notes that 50% of infertility cases are linked to the male partner. The company is expanding nationwide and building a growing team of reproductive urologists. Dr. William Schoolcraft joined as a strategic advisor to support clinician and public education on early male fertility evaluation. Posterity Health is the only digital male fertility center of excellence offering personalized advice, educational resources, and effective male fertility treatments. Its Digital Health Platform combines virtual visits, at-home diagnostics, and in-person consultations and delivers services including baseline assessments, sperm preservation, semen analysis, pregnancy loss consults, diagnostic workups, vasectomy reversals, and gender-affirming care. The company deploys care protocols developed with a Medical Advisory Board that includes leaders from Weill Cornell, UCSF, and Yale. Posterity plans to use the $7.5M oversubscribed round to accelerate its Digital Health Platform and expand national access to male fertility testing and treatment, doubling the number of reproductive urologists on its network. The expansion is timed to capitalize on new male fertility benefits that became effective January 1, 2023. Early data from a hormone management study showed nearly 70 percent of males receiving hormone management therapy had an improved sperm count, which the company cites as validation of its care model. Posterity Health operates a digital male fertility platform that provides personalized advice, educational resources, and treatments aimed at addressing male contributors to infertility. Its telehealth offering, Male Factor Management, delivers virtual visits, at-home diagnostics, and in-person consults. Services include baseline assessments, sperm preservation, semen analysis, pregnancy loss consults, diagnostic workups, vasectomy reversals, and gender-affirming care. The company emphasizes education and engagement through its digital platform combined with at-home testing as a key differentiator. Posterity launched service in Colorado, currently provides care in 26 states, and has a team of 15 people. Founders Pam Pure (CEO) and Barrett Cowan (co-founder and CMO) plan to grow the clinical team and partnerships while expanding services nationwide.

Participated · Series B · Apr 2024

Headquartered in Palo Alto, Midi Health operates a nationwide virtual clinic that addresses gaps in women’s healthcare from perimenopause and menopause to broader chronic and preventive needs. The company’s proprietary AI engine analyzes patient charts to personalize diagnosis, streamline scheduling and documentation, and continuously refine clinical protocols using one of the industry’s largest women’s-health datasets. Midi currently has insurance contracts that give more than 45 million U.S. women in-network access to its services, and over 25,000 patients seek care on the platform each week. Outcomes data show a 28-percentage-point increase in breast-cancer screening adherence, an 11-point rise in colorectal screening adherence, and up to a 13 percent reduction in total cost of care, alongside clinically significant reductions in A1c and LDL levels. The business complements its clinical model with an expanding specialist roster covering OB-GYN, cardiology, endocrinology, mood disorders, dermatology, longevity, and more. Recent executive hires from Tesla, Google, Meta, Lyft, and Omada Health signal a push to scale operations and brand awareness. Following its latest financing, Midi is valued at more than $1 billion and plans to broaden its AI capabilities and extend comprehensive women’s care across every life stage.

Participated · Series A · Feb 2023

Twentyeight Health is a NYC-based digital-first women’s healthcare platform that makes reproductive and sexual healthcare affordable through telemedicine consultations, fast at-home deliveries, and ongoing access to providers for services such as birth control and herpes treatments. The company accepts almost every commercial insurance and Medicaid plan, positioning itself as a broadly accessible alternative to traditional care. It currently serves more than 100,000 users across 43 states. Twentyeight Health raised $10M in a Series A, bringing its total capital raised to $25M. The company intends to use the funds to expand operations and accelerate product development. Bruno Van Tuykom serves as CEO. Twentyeight Health operates a women’s virtual healthcare platform focused on sexual and reproductive care, accepting Medicaid and partnering with culturally competent clinicians. The platform is bilingual (English and Spanish) and aims to serve medically underserved, low-income, and non-urban populations. Since founding in 2018, the company has expanded from six to 34 states and now covers more than 85% of women of reproductive age in the U.S. It has helped over 60,000 individuals access care, with 55% of users on Medicaid, 58% identifying as BIPOC, and 60% living in non-urban areas; 63% of its birth-control users previously lacked access to prescriptions. The company offers free birth control to uninsured users through a partnership with the Contraceptive Access Fund of Bedsider and donates 2% of revenues to related organizations. With recent funding, Twentyeight Health plans to expand nonprofit partnerships, grow its services and footprint, and improve the quality of its telehealth offerings. Twentyeight Health offers telemedicine reproductive-health services focused on contraception, providing online medical questionnaires reviewed by U.S. board-certified doctors and access to more than 100 FDA-approved birth control options. Customers receive shipments within three days and ongoing care via audio consultations and doctor follow-up messages. The company emphasizes serving Medicaid, underinsured, and uninsured women and works with partners such as Bottomless Closet and eight CUNY colleges to reach underserved populations. Twentyeight Health is the only telemedicine contraception provider noted in the article that accepts Medicaid and also partners with Bedsider’s Contraceptive Access Fund to provide free birth control to uninsured patients. The company donates 2% of its revenue to Bedsider and the National Institute for Reproductive Health. Launched in 2018, Twentyeight Health currently operates across Florida, Maryland, New York, New Jersey, North Carolina, and Pennsylvania and plans to use new funding to expand services across the U.S.

Participated · Series A · Sep 2022

Proov (MFB Fertility, Inc.) develops at-home hormone tests and created the first and only FDA-cleared PdG-testing kit to confirm ovulation quality. Its patented PdG protocol and the Proov Insight app provide quantitative hormone results, end-of-cycle reports, and stored hormone trends without an external reader. The company expanded its product lineup to include Proov Predict & Confirm and has launched Proov Complete, an at-home suite that measures FSH, LH, E1G (estrogen marker) and PdG. Proov says the Complete product and app deliver a comprehensive and affordable at-home hormonal pattern analysis across the menstrual cycle. The company was originally co-founded in Boulder, Colo. by two women who struggled to conceive and is led by CEO Amy Beckley. Proov raised a Series A to support the Complete product and to expand accessibility and physician partnerships. Proov is an at-home fertility diagnostics company launched by MFB Fertility Inc. in 2018 and co-founded in Boulder, Colorado by two women who struggled to conceive. Its FDA-approved test measures the progesterone metabolite PdG in urine to help women confirm ovulation; low progesterone is cited as a leading cause of infertility and preventable miscarriage. Demand for at-home testing kits has surged amid Covid-19, driving the company to scale production and accelerate research and development. The company recently received undisclosed funding from Lightship Capital and the Texas HALO Fund, plus additional angel investors, to support growth and new product launches. Proov also holds a $1.3 million contract with the U.S. Air Force to provide free kits and connect military couples with fertility specialists. CEO Amy Beckley said the investment will help Proov expand its product offering and continue developing fertility tools to deliver more accessible reproductive-health solutions.